Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Crit Care Med. Feb 4, 2016; 5(1): 1-6
Published online Feb 4, 2016. doi: 10.5492/wjccm.v5.i1.1
Published online Feb 4, 2016. doi: 10.5492/wjccm.v5.i1.1
New pharmacological approaches against chronic bowel and bladder problems in paralytics
Pierre A Guertin, Department of Psychiatry and Neurosciences, Laval University, Pavillon Vandry, Québec, QC G1V 0A6, Canada
Pierre A Guertin, Laval University Medical Center (CHU de Québec - CHUL), Québec, QC G1V 4G2, Canada
Author contributions: Guertin PA solely contributed to all aspects of this editorial paper.
Conflict-of-interest statement: The author is also president and chief executive officer of Nordic Life Science Pipeline.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Pierre A Guertin, PhD, Professor, Laval University Medical Center (CHU de Québec - CHUL), 2705 Laurier Boulevard, RC-9800 (Neuroscience), Québec, QC G1V 4G2, Canada. pierre.guertin@crchul.ulaval.ca
Telephone: +1-418-5254444-48831 Fax: +1-418-6542753
Received: May 13, 2015
Peer-review started: May 20, 2015
First decision: July 6, 2015
Revised: September 15, 2015
Accepted: November 10, 2015
Article in press: November 11, 2015
Published online: February 4, 2016
Peer-review started: May 20, 2015
First decision: July 6, 2015
Revised: September 15, 2015
Accepted: November 10, 2015
Article in press: November 11, 2015
Published online: February 4, 2016
Core Tip
Core tip: This editorial is one of the first to describe clearly the existence of an urgent medical need for new pharmacological products aimed at providing non-invasive solutions for those suffering chronically of constipation and urinary retention or detrusor-sphincter dyssynergia. Products combining several already known and safe active ingredients for new or synergistic effects acting upon specific central networks of neurons that normally control these functions are of particular interest.